|
KMID : 0338420210360040942
|
|
The Korean Journal of Internal Medicine
2021 Volume.36 No. 4 p.942 ~ p.948
|
|
|
Impact of urgently initiated tele-prescription due to COVID-19 on glycemic control in patients with type 2 diabetes
|
|
Park Sung-Don
Kim Na-Young
Jeon Jae-Han
Kim Jung-Guk
Lee In-Kyu
Park Keun-Gyu
Choi Yeon-Kyung
|
|
|
Abstract
|
|
|
Background/Aims: Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than 13,000 people in South Korea by July 2020. To prevent spread of COVID-19, tele-prescription was permitted temporarily. This study investigated the impact of tele-prescription on glycemic control in patients with type 2 diabetes.
Methods: Glycated hemoglobin (HbA1c) concentrations were retrospectively analyzed in patients with type 2 diabetes who were treated with tele-prescription because of COVID-19 and those who were treated by face-to-face care (non-tele-prescription group) enrolled at the same period of time. Mean HbA1c concentrations and mean change in HbA1c concentration (ΔHbA1c) were compared in these two groups.
Results: The mean HbA1c levels of patients were significantly higher after than before the tele-prescription period (7.46% ± 1.24% vs. 7.27% ± 1.13%, p < 0.05). Mean ΔHbA1c was significantly higher in the tele-prescription than in the non-tele-prescription group (0.19% ± 0.68% vs. 0.04% ± 0.95%, p < 0.05). HbA1c was significantly greater in patients taking fewer oral hypoglycemic agents, no insulin, fewer comorbidities (e.g., coronary artery disease, cerebrovascular accident, and diabetic neuropathy), and higher baseline HbA1c.
Conclusions: Tele-prescription may worsen glycemic control in patients with type 2 diabetes during public health crises.
|
|
|
KEYWORD
|
|
|
COVID-19, Tele-prescription, Glycated hemoglobin A, Diabetes mellitus, type 2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|